Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
Participants
Cystic Fibrosis - 18 Years and older (Adult, Older Adult)
Interventions
Drug: ABBV-3067|Drug: Placebo ABBV-3067|Drug: ABBV-2222|Drug: Placebo ABBV-2222
Outcome measures
Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Absolute change in sweat chloride (SwCl)|Absolute change in forced vital capacity (FVC)|Absolute change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Relative change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in forced vital capacity (FVC)